ライフサイエンスコーパス: tricuspid

1 cording to valve morphology (bicuspid versus tricuspid).

2 Of the concurrent valve procedures, 56 were tricuspid, 13 aortic, and 6 mitral.

3 with aortic stenosis (2726 bicuspid; 79 096 tricuspid), 2691 propensity-score matched pairs of bicus

4 uctions in both mitral (34.9% vs. 12.7%) and tricuspid (31.8% vs. 21.2%) moderate or severe regurgita

5 6 cases of BPVT (11.6%; aortic 29, mitral 9, tricuspid 7, pulmonary 1), mean age was 63 years, and 68

6 The following review will describe tricuspid anatomy, define echocardiographic views for ev

7 specific models of severe aortic stenosis (6 tricuspid and 2 bicuspid) were created using dual-materi

8 smutase 3 in ascending aorta samples from 50 tricuspid and 70 patients with BAV undergoing surgery fo

9 icular tachycardia originating from the peri-tricuspid and mitral annuli.

10 pared with earlier measurements, and indexed tricuspid and neoaortic annular area decreased from 14 m

11 The prevalence of >=moderate tricuspid and neoaortic regurgitation was uncommon and d

12 esser degrees of tricuspid regurgitation and tricuspid annular dilatation, as well as with appreciati

13 ity of TR, but also pays strict attention to tricuspid annular dilation (size), the mode of tricuspid

14 Routine treatment of moderate TR or tricuspid annular dilation at the time of MV repair appe

15 for moderate tricuspid regurgitation (TR) or tricuspid annular dilation in patients undergoing degene

16 In patients with moderate TR or tricuspid annular dilation who were undergoing degenerat

17 ricuspid annuloplasty for moderate TR and/or tricuspid annular dilation.

18 Left ventricular ejection fraction, tricuspid annular peak systolic excursion, and systolic

19 Tricuspid annular plane excursion and RV strain did not

20 , end-systolic area, fractional area change, tricuspid annular plane excursion, and RV speckle-tracki

21 as defined by semiquantitative assessment or tricuspid annular plane systolic excursion </=15 mm, HFp

22 duction of RV function, according to a lower tricuspid annular plane systolic excursion ( P=0.003) an

23 cuspid regurgitation velocity (27%-41%), and tricuspid annular plane systolic excursion (13%) (P<0.05

24 IQR 8.9-2.4]; P < 0.0001) and mean ( +/- SD) tricuspid annular plane systolic excursion (2.2 +/- 0.12

25 ce interval, 1.01-1.11; P=0.01) and exercise tricuspid annular plane systolic excursion (odds ratio,

26 At 24 hours, lower tricuspid annular plane systolic excursion (P = 0.004) a

27 tricuspid regurgitation, in comparison with tricuspid annular plane systolic excursion (TAPSE) and f

28 baseline in 17beta-estradiol levels (E2) and tricuspid annular plane systolic excursion (TAPSE) at 3

29 ll-cause death during follow-up according to tricuspid annular plane systolic excursion (TAPSE) quart

30 ble Cox proportional-hazards model, exercise tricuspid annular plane systolic excursion (TAPSE; hazar

31 re examined relative to the severity of RVD (tricuspid annular plane systolic excursion [TAPSE]) and

32 d assessment of RV chamber function included tricuspid annular plane systolic excursion and fractiona

33 of RV-to-left ventricular diameter ratio and tricuspid annular plane systolic excursion and improveme

34 ocity; and worse right ventricular function (tricuspid annular plane systolic excursion and right ven

35 Tricuspid annular plane systolic excursion correlated wi

36 uctive pulmonary disease (P = 0.034) and the tricuspid annular plane systolic excursion to systolic p

37 valvular heart disease (P = 0.046), and the tricuspid annular plane systolic excursion to systolic p

38 RVD defined by tricuspid annular plane systolic excursion values showed

39 Tricuspid annular plane systolic excursion was not diffe

40 bnormalities were frequent: 28% had abnormal tricuspid annular plane systolic excursion, 15% had redu

41 troke volume/pulmonary pulse pressure ratio, tricuspid annular plane systolic excursion, 6-minute wal

42 olume index, LV filling pressure estimation, tricuspid annular plane systolic excursion, and systolic

43 cise mitral regurgitation, rest and exercise tricuspid annular plane systolic excursion, exercise sys

44 s to show the feasibility of a transcatheter tricuspid annular repair.

45 03 and 2011, 419 (65%) underwent concomitant tricuspid annuloplasty for moderate TR and/or tricuspid

46 to compare a strategy of routine concomitant tricuspid annuloplasty for moderate tricuspid regurgitat

47 Associated tricuspid annuloplasty is recommended during left-heart

48 oing degenerative mitral repair, concomitant tricuspid annuloplasty is safe, effective, and associate

49 e indications for and results of concomitant tricuspid annuloplasty remain controversial.

50 roups, but multivariate analysis showed that tricuspid annuloplasty was independently associated with

51 a novel transcatheter device to plicate the tricuspid annulus (TA) and reduce tricuspid regurgitatio

52 ded during left-heart valve surgery when the tricuspid annulus (TA) is dilated but methodology for th

53 mmend TV repair in the presence of a dilated tricuspid annulus at the time of a left-sided valve surg

54 th PEX than in controls, both measured using tricuspid annulus plane systolic excursion (stress, 25.0

55 Tricuspid annulus plane systolic excursion decreased and

56 High Z(va) and low tricuspid annulus plane systolic excursion were associat

57 pective of treatment arm, high Z(va) and low tricuspid annulus plane systolic excursion, but not mode

58 annulus>=40 mm) and RV systolic dysfunction (tricuspid annulus systolic excursion plane<17 mm): patte

59 ed according to the presence of RV dilation (tricuspid annulus>=40 mm) and RV systolic dysfunction (t

60 patients, mitral annulus, crista terminalis, tricuspid annulus, and right-sided PV via a posterior co

61 ion between vena cavae and right atrium; the tricuspid annulus; or between TV leaflets, improving coa

62 ate was significantly higher for bicuspid vs tricuspid aortic stenosis (2.5% vs 1.6%; HR, 1.57 [95% C

63 different between patients with bicuspid and tricuspid aortic stenosis at 30 days (2.6% vs 2.5%; haza

64 r aortic stenosis, patients with bicuspid vs tricuspid aortic stenosis had no significant difference

65 opensity-score matched pairs of bicuspid and tricuspid aortic stenosis were analyzed (median age, 74

66 TAVR for bicuspid vs tricuspid aortic stenosis.

67 n patients undergoing surgery for BAV versus tricuspid aortic valve (TAV) stenosis.

68 rum concentration significantly decreased in tricuspid aortic valve and BAVnon-dil patients versus he

69 In this series of patients with tricuspid aortic valve and similar AS severity, women ha

70 tion-based MI registry (n=403).Compared with tricuspid aortic valve disease, CAE occurred more than t

71 scatheter aortic valve replacement (TAVR) in tricuspid aortic valve has been developed, which can pre

72 spected aortic valve disease (n=94 BAV, n=83 tricuspid aortic valve) underwent both cardiac magnetic

73 lot in ascending aorta samples from other 10 tricuspid aortic valve, 10 BAVnon-dil, and 10 BAVdil pat

74 ts with BAV when compared with patients with tricuspid aortic valve.

75 or computed tomography were compared with 88 tricuspid aortic valves (TAV) patients.

76 ic and lipidomic consequences of rs174547 in tricuspid aortic valves from patients with AS.

77 cification than those Npr2(+/-) with typical tricuspid aortic valves or all wild-type littermate cont

78 Explanted stenotic tricuspid aortic valves were weighed, and fibrosis degre

79 nscriptomic analyses were performed in human tricuspid aortic valves.

80 3-dimensional echocardiogram focused on the tricuspid apparatus.

81 althy controls showed a 37% increment in the tricuspid area during exercise, compared with 4% in pati

82 ies: tetralogy of Fallot (15 patients, 25%), tricuspid atresia (12 patients, 20%), Ebstein's anomaly

83 l Wnt signaling in the myocardium results in tricuspid atresia with hypoplastic right ventricle assoc

84 Initially designed for patients with tricuspid atresia, this procedure is now offered for a v

85 arable following TAVR for bicuspid AV versus tricuspid AV disease.

86 tients with bicuspid AV versus patients with tricuspid AV in the Medicare-linked cohort, whereas no d

87 id AV stenosis in comparison with those with tricuspid AV stenosis.

88 s was slightly lower in the bicuspid (versus tricuspid) AV group (96.3% in bicuspid versus 97.4% in t

89 was significantly higher in the bicuspid vs tricuspid cohort (0.9% vs 0.4%, respectively; absolute r

90 ficant correlations were found among tau and tricuspid deceleration time, E', E/E', TimeE-E', A wave

91 l thickness was increased and an increase in tricuspid E, A peaks and an elevated E/A.

92 RHF for patients with significant preimplant tricuspid insufficiency.

93 r plane systolic excursion ( P=0.003) and RV tricuspid lateral annular systolic velocity ( P=0.02), a

94 We hypothesized that tricuspid leaflet area (TLA) is increased in PH, and tha

95 icuspid annular dilation (size), the mode of tricuspid leaflet coaptation, and tricuspid leaflet teth

96 and underwent device implantation to improve tricuspid leaflet coaptation, thereby reducing TR.

97 he mode of tricuspid leaflet coaptation, and tricuspid leaflet tethering-factors often influenced by

98 AV group (96.3% in bicuspid versus 97.4% in tricuspid, P=0.07), with a slightly higher incidence of

99 Tricuspid regurgitant (TR) jet velocity and its relation

100 Quantitation of tricuspid regurgitant (TR) severity can be challenging w

101 We assessed vascular complications (elevated tricuspid regurgitant jet velocity [TRV], microalbuminur

102 Elevated tricuspid regurgitant jet velocity, pulmonary hypertensi

103 ery systolic pressure (PASP) >35 mmHg and/or tricuspid regurgitant velocity (TRV) >2.5 m/s.

104 with sickle cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler

105 terest in the treatment of severe functional tricuspid regurgitation (FTR) due to the awareness of it

106 t of the etiology and severity of functional tricuspid regurgitation (FTR) has many limitations, espe

107 Functional tricuspid regurgitation (FTR) is common in heart failure

108 ated with left heart pathologies, functional tricuspid regurgitation (FTR) is often left untreated du

109 n multivariable analysis, moderate or severe tricuspid regurgitation (hazard ratio [HR], 26.537; 95%

110 olic dimension and volume index, >= moderate tricuspid regurgitation (TR) (7%, 35%, and 53%, respecti

111 12.5%, persistent or new moderate or severe tricuspid regurgitation (TR) 20.8%, and new atrial fibri

112 despite the known association between severe tricuspid regurgitation (TR) and mortality.

113 Tricuspid regurgitation (TR) and right ventricular (RV)

114 cal and medical treatment options for severe tricuspid regurgitation (TR) are limited, and additional

115 face for native leaflet coaptation to reduce tricuspid regurgitation (TR) by occupying the regurgitan

116 ndergoing upright invasive exercise testing, tricuspid regurgitation (TR) Doppler estimates and invas

117 Patients with severe tricuspid regurgitation (TR) frequently present with exe

118 Patients with isolated tricuspid regurgitation (TR) in the absence of left-side

119 Tricuspid regurgitation (TR) is a common and important c

120 Tricuspid regurgitation (TR) is a risk factor for mortal

121 Severe tricuspid regurgitation (TR) is associated with high mor

122 Tricuspid regurgitation (TR) is common among adults with

123 (FTR) has many limitations, especially when tricuspid regurgitation (TR) is more than severe.

124 Functional or secondary tricuspid regurgitation (TR) is the most common cause of

125 The presence of tricuspid regurgitation (TR) may affect prognosis in pat

126 However, significant tricuspid regurgitation (TR) often accompanies left-side

127 comitant tricuspid annuloplasty for moderate tricuspid regurgitation (TR) or tricuspid annular dilati

128 Functional tricuspid regurgitation (TR) with a structurally normal

129 ients with significant (moderate and severe) tricuspid regurgitation (TR), the decision to intervene

130 licate the tricuspid annulus (TA) and reduce tricuspid regurgitation (TR).

131 94; 95% CI, 0.89-0.99; P=0.027), and </=mild tricuspid regurgitation (TR; HR, 3.58; 95% CI, 2.04-6.30

132 Importantly, moderate or severe mitral and tricuspid regurgitation also decreased (33.7% vs. 8.6% [

133 oppler echocardiography variables (including tricuspid regurgitation and pulmonary regurgitation) and

134 with recognition of the risk of progressive tricuspid regurgitation and right heart failure in patie

135 patients with moderate or lesser degrees of tricuspid regurgitation and tricuspid annular dilatation

136 owever, many patients with unoperated severe tricuspid regurgitation are also deemed at very high or

137 Most operations for tricuspid regurgitation are done at the time of left-sid

138 cations for tricuspid valve surgery to treat tricuspid regurgitation are related to the cause of the

139 ictive ring annuloplasty repair of secondary tricuspid regurgitation at the time of left-sided valve

140 appears to be safe and effective at reducing tricuspid regurgitation by at least one grade.

141 2011, to August 28, 2013) and had measurable tricuspid regurgitation by spectral Doppler.

142 pulmonary artery pressure assessed from the tricuspid regurgitation derived maximal pressure gradien

143 actor for mortality in patients with chronic tricuspid regurgitation due to acquired heart disease.

144 Overall, tricuspid regurgitation estimated systolic pressure grad

145 After TVIV, both the TV inflow gradient and tricuspid regurgitation grade improved significantly.

146 , right heart failure and moderate-to-severe tricuspid regurgitation in 5/6 CRS type II patients.

147 anomaly is the most common cause of primary tricuspid regurgitation in adults with congenital heart

148 medically managed patients with >= moderate tricuspid regurgitation in Europe and North America (n =

149 es have begun to emerge for the treatment of tricuspid regurgitation in such patients.

150 sed and the percentage of moderate or severe tricuspid regurgitation increased from baseline to 1 yea

151 Tricuspid regurgitation is a prevalent disease associate

152 Tricuspid regurgitation is associated with increased rat

153 Severe tricuspid regurgitation is associated with poor prognosi

154 Whereas tricuspid stenosis is uncommon, tricuspid regurgitation is frequently encountered and is

155 Marked tricuspid regurgitation is frequently present in patient

156 unction and stiffness associations with ECV, tricuspid regurgitation jet velocity (TRV) and exercise

157 high risks of reoperative surgery for severe tricuspid regurgitation late after left-sided valve surg

158 Tricuspid regurgitation maximal velocity greater than 2.

159 Tricuspid regurgitation maximal velocity pressure gradie

160 Worsening systemic RV function and tricuspid regurgitation may develop after LVOT TPVR.

161 Non-invasive assessment of tricuspid regurgitation must define its cause and severi

162 ividuals with plasma endothelin-1 levels and tricuspid regurgitation on echocardiogram (n = 3223) at

163 was limited to participants with detectable tricuspid regurgitation on echocardiography.

164 f lead-related (as distinct from functional) tricuspid regurgitation pose unique challenges.

165 al velocity greater than 2.82 m/s as well as tricuspid regurgitation pressure gradient greater than 3

166 moderate (2 patients) or severe (6 patients) tricuspid regurgitation recorded at either initial or re

167 (TrIcuspid Regurgitation RePAIr With CaRdioband Transcath

168 R in 30 patients enrolled in the TRI-REPAIR (TrIcuspid Regurgitation RePAIr With CaRdioband Transcath

169 interval, 1.2-3.3; P=0.0053]) and preimplant tricuspid regurgitation severity (odds ratio=2.9 [95% co

170 primary efficacy endpoint was a reduction in tricuspid regurgitation severity by at least one grade a

171 Tricuspid regurgitation severity was reduced by at least

172 Tricuspid regurgitation severity was the most important

173 ion mediated 19%-35%), E/e' ratio (18%-29%), tricuspid regurgitation velocity (27%-41%), and tricuspi

174 with established clinical risk factors using tricuspid regurgitation velocity, white blood cell count

175 increased mitral E velocity, E/e' ratio, and tricuspid regurgitation velocity; and worse right ventri

176 Tricuspid regurgitation was graded using a five-class gr

177 ome, higher FTR degree compared with trivial tricuspid regurgitation was independently associated wit

178 Tricuspid regurgitation was massive (46 mL) (Figs 1-4).

179 Worsening of systemic RV dysfunction or tricuspid regurgitation was seen in 12 patients (57%) an

180 s [62-78 years]) with significant functional tricuspid regurgitation were divided according to the pr

181 ermore, patients with significant preimplant tricuspid regurgitation who did not receive a TVP experi

182 ty System for Symptomatic Chronic Functional Tricuspid Regurgitation) trial is a prospective, single-

183 HD: 3101 had mitral regurgitation, 1179 with tricuspid regurgitation, 817 had aortic regurgitation, 4

184 weight (n=472), adjusting for sex, syndrome, tricuspid regurgitation, arch obstruction, and shunt typ

185 renal replacement therapy, severe preimplant tricuspid regurgitation, history of cardiac surgery, and

186 Conclusions In significant tricuspid regurgitation, impaired RV free wall longitudi

187 rain in patients with significant functional tricuspid regurgitation, in comparison with tricuspid an

188 ght ventricular dysfunction, moderate-severe tricuspid regurgitation, low cardiac index, and raised r

189 The severity of tricuspid regurgitation, myocardial performance index, p

190 atation, pulmonary hypertension, severity of tricuspid regurgitation, or individual mitral regurgitat

191 l haemodynamic abnormalities (more than mild tricuspid regurgitation, residual ventricular septal def

192 ound In patients with significant functional tricuspid regurgitation, timely detection of right ventr

193 ation; inclusions bias related to detectable tricuspid regurgitation, which may limit generalizabilit

194 ht ventricular systolic function and greater tricuspid regurgitation, which persisted at 1 year.

195 tricuspid valve repair system, for reducing tricuspid regurgitation.

196 or severe lung disease, dialysis, and severe tricuspid regurgitation.

197 on because of progressive RV dysfunction and tricuspid regurgitation.

198 nscatheter tricuspid valve repair for severe tricuspid regurgitation.

199 ificantly associated with mortality, but not tricuspid regurgitation.

200 om restrictive myocardial disease and severe tricuspid regurgitation.

201 ht ventricular dilation and dysfunction, and tricuspid regurgitation.

202 in combination with right heart failure, and tricuspid regurgitation; and (iii) a typical histopathol

203 The RV hemodynamic alteration after tricuspid repair could be used to predict the success of

204 there was no difference in survival between tricuspid repair versus replacement (hazard ratio: 1.53;

205 d 2005, 48 patients with ES, all with a post-tricuspid shunt, were enrolled in a prospective, longitu

206 ients with a common atrioventricular, single tricuspid, single mitral, and 2 atrioventricular valves

207 Whereas tricuspid stenosis is uncommon, tricuspid regurgitation

208 ndependently associated with 4D flow derived tricuspid stroke volume and RV blood flow KE E/A ratio.

209 Few patients undergo isolated tricuspid surgery, which remains associated with high in

210 5.5 vs 35.4 mm +/- 3.7; P < .0001), and the tricuspid systolic wave was also smaller (stress, 16.9 c

211 opheus specimens, a small morphotype bearing tricuspid teeth and a large morphotype bearing single-cu

212 investigate the effect of healthy ageing on tricuspid through-plane flow and right ventricular blood

213 in the superior and inferior caval veins and tricuspid valve (adjusted r = 0.28-0.55; all P < .01), p

214 Porcine tricuspid valve (TV) (n = 3) was extracted and incorpora

215 ntation (TVIV) within dysfunctional surgical tricuspid valve (TV) bioprostheses has been described in

216 assess the remodeling potential of a tubular tricuspid valve (TV) bioprosthesis made of SIS-ECM by ev

217 Tricuspid valve (TV) disease has been relatively neglect

218 Severe tricuspid valve (TV) dysfunction may lead to surgical TV

219 le electronic device leads to interfere with tricuspid valve (TV) function has gained increasing reco

220 Severe isolated disease of the tricuspid valve (TV) is increasing and results in intrac

221 egurgitation (TR) with a structurally normal tricuspid valve (TV) may occur secondary to chronic atri

222 enosis or regurgitation after prior surgical tricuspid valve (TV) replacement or repair.

223 rmined by factors in the right ventricle and tricuspid valve and not the timing of or the type of sur

224 cardiographic dataset at baseline revealed a tricuspid valve annular area of 14.1 cm(2), and effectiv

225 Only 98 (8%) patients underwent tricuspid valve annuloplasty during follow-up.

226 ly Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known a

227 The SCOUT (Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chro

228 95% confidence interval, 3.5-21.0; P<0.001), tricuspid valve annulus diameter z-score (odds ratio, 1.

229 ining the lateral tunnel suture line and the tricuspid valve annulus.

230 tant TVI is safe and results in better early tricuspid valve competence than isolated PVR.

231 lantation, for 20 (3.0%) total patients with tricuspid valve complications.

232 e damage (Stage 2), pulmonary vasculature or tricuspid valve damage (Stage 3), or right ventricular d

233 ter z score was lower (P<0.001) and the mean tricuspid valve diameter z score was higher in fetuses w

234 nscatheter interventions to treat mitral and tricuspid valve disease are becoming increasingly availa

235 The assessment and management of tricuspid valve disease have evolved substantially durin

236 ole of cross-sectional imaging in mitral and tricuspid valve disease, primarily valvular regurgitatio

237 integrated into the evaluation of mitral and tricuspid valve disease.

238 LP therapy is associated with an increase in tricuspid valve dysfunction through 12 months of follow-

239 Ebstein anomaly and tricuspid valve dysplasia are rare congenital tricuspid

240 Fetuses diagnosed with Ebstein anomaly and tricuspid valve dysplasia from 2005 to 2011 were include

241 y series of fetuses with Ebstein anomaly and tricuspid valve dysplasia, perinatal mortality remained

242 lip device was successfully implanted in the tricuspid valve in 97% of the cases.

243 ed normal intracardiac connections, with the tricuspid valve in the normal position and normal size o

244 tion of the LP was associated with increased tricuspid valve incompetence (odds ratio, 5.20; P=0.03).

245 IDU-IE patients more frequently had tricuspid valve infection, Staphylococcus infection, and

246 Among patients with available data, tricuspid valve injury was documented in 11 (1.7%), and

247 sought to evaluate the impact of concomitant tricuspid valve intervention (TVI) on post-operative TR,

248 t selection in future trials to determine if tricuspid valve intervention improves outcomes in this h

249 Transcatheter tricuspid valve interventions (TTVI) are promising, but

250 Surgical mortality for isolated tricuspid valve interventions remains higher than for an

251 .6 million Americans suffer from significant tricuspid valve leakage.

252 icular heart failure in sheep that developed tricuspid valve leakage.

253 pothesis, we set out to demonstrate that the tricuspid valve maladapts in disease.

254 lenge this paradigm and hypothesize that the tricuspid valve maladapts in those patients rendering th

255 ricuspid valve dysplasia are rare congenital tricuspid valve malformations associated with high perin

256 efine echocardiographic views for evaluating tricuspid valve morphology and function, and discuss ima

257 gh this seemed to be predominantly driven by tricuspid valve or pulmonary artery vasculature damage (

258 itral valve or left atrial damage), Stage 3 (tricuspid valve or pulmonary artery vasculature damage),

259 propose a new staging system for functional tricuspid valve pathology using 3 parameters that may mo

260 y pressure of more than 60 mm Hg, a previous tricuspid valve procedure, or a cardiovascular implantab

261 ) as independent predictors while concurrent tricuspid valve procedures (TVP) were not predictors.

262 th safety and performance of a transcatheter tricuspid valve reconstruction system in the treatment o

263 The changes in tricuspid valve regurgitation in the LP group were simil

264 Tricuspid valve regurgitation was graded as being more s

265 rgery, and concomitant procedures other than tricuspid valve repair at the time of LVAD.

266 Transcatheter tricuspid valve repair could become an effective treatme

267 the first-in-human successful transcatheter tricuspid valve repair for severe tricuspid regurgitatio

268 antable cardiac defibrillator, and mitral or tricuspid valve repair or replacement, can be (partially

269 s such as cardiac resynchronization therapy, tricuspid valve repair or replacement, pulmonary artery

270 nalysed in all patients who had an attempted tricuspid valve repair procedure upon femoral vein punct

271 TriClip, a minimally invasive transcatheter tricuspid valve repair system, for reducing tricuspid re

272 ge-to-edge repair technique with the TriClip tricuspid valve repair system.

273 Patients undergoing tricuspid valve repair were older (mean age 59.2 years v

274 al role in guiding the procedure (mitral and tricuspid valve repair, left atrial appendage closure, a

275 to benefit from leaflet augmentation during tricuspid valve repair.

276 All had tricuspid valve replacement (159 bioprostheses, 36 mecha

277 m valve-related outcomes after transcatheter tricuspid valve replacement (TTVR), including valve func

278 ocardiographic indices of RV, neoaortic, and tricuspid valve size and function at 14 months, pre-Font

279 odel, KEi(EDV) E/A ratio and 4D flow derived tricuspid valve stroke volume demonstrated independent a

280 In the subset of patients who underwent tricuspid valve surgery (n = 344), a post-operative impr

281 roperatively in 120 patients who underwent a tricuspid valve surgery and using TTE (A4C) in 66 health

282 ry bypass grafting, and/or aortic, mitral or tricuspid valve surgery in Ontario, Canada, between 2008

283 Isolated tricuspid valve surgery is associated with high morbidit

284 The indications for tricuspid valve surgery to treat tricuspid regurgitation

285 with isolated severe TR, 171 (5%) underwent tricuspid valve surgery, including 143 (84%) repairs and

286 now include echocardiographic parameters of tricuspid valve tenting area, and associated right ventr

287 The TriValve (Transcatheter Tricuspid Valve Therapies) registry collected 472 patien

288 The tricuspid valve was virtually ignored for a long time in

289 ricular (RV) pacing are well-known causes of tricuspid valve, mitral valve, and cardiac dysfunction.

290 orm the transcatheter bicuspidization of the tricuspid valve, the Mitralign system was used to place

291 er aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysf

292 atrioventricular valve, and 97 had a single tricuspid valve.

293 that extends posteriorly to the plane of the tricuspid valve.

294 es, good operator technique, and a competent tricuspid valve.

295 Patients with a tricuspid-valve regurgitant jet velocity >/=3.2 m/s (3.6

296 In comparison with patients with tricuspid valves, patients with bicuspid AV were younger

297 with bicuspid aortic valves than those with tricuspid valves.

298 ater gives rise to the septum and mitral and tricuspid valves.

299 many currently untreated patients with leaky tricuspid valves.

300 n pulmonary valves, 22 mitral valves, and 21 tricuspid valves.